Chronic Pain Clinical Trial
Official title:
Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Pilot Study, Followed by an Open-Label Extension Phase
Seeking for effective therapeutic strategies, the investigators are proposing to test the effectiveness of different formulations of medical cannabis oil to alleviate chronic pain, which was partially relieved with conventional prescriptions. Furthermore, the investigators would like to assess the effect of different formulations of medical cannabis oil on other symptoms associated to chronic pain like anxiety and depression, as well as insomnia and appetite. Finally, as recently recommended for clinical studies on medical cannabis, the investigators will examine the safety profile of different cannabis formulations focusing on the following elements: a real chronic administration with more than two weeks of treatment, a larger number of patients, and the clinical relevance of medical cannabis oil to change the amount and type of concomitant medications used to control chronic non-cancer and cancer pain.
This is a 6-week randomized, double-blind, placebo-controlled, parallel group design trial
followed by an open-label extension phase of 12 weeks, to evaluate the safety and efficacy of
different formulations of medical cannabis oil to reduce chronic pain intensity.
The study will be conducted at Santé Cannabis Clinic, the only medical cannabinoid therapy
clinic, located in Montreal, Quebec. One hundred and sixty consecutive adult patients, male
and female, with chronic non-cancer and cancer pain (at least 3 months in duration), with an
average weekly pain intensity score greater than 4 on the 11 points NRS, will be
prospectively recruited and invited to participate in this trial.
Informed consent will be obtained by a Research Assistant.
After baseline documentation with standardized scales, patients will be randomized to one of
4 parallel groups:
- Group A: THC/CBD ratio 1:1 capsule
- Group B: THC/CBD ratio 1:2 capsule
- Group C: THC/CBD ratio 0.1:2 capsule
- Group D: Placebo capsule Patients will have a dose titration phase during the first
week. The dose escalation will allow patients to adapt to the potential adverse effects
(AEs) of the medical cannabis.
Follow-up visits will be done after 1 week and 6 weeks of treatment. At the end of the first
phase of the study, patients who wish to participate in the open-label extension phase will
have the option to continue in the same treatment regimen. For the placebo group, the
investigator may propose one of the cannabis oils to the subject if they feel it may
potentially provide benefits.
They will take this new treatment for other 12 weeks. For this open-label extension phase the
follow-up visits will be done after 4 weeks and 12 weeks of treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|